Cargando…

Knowledge mapping of targeted immunotherapy for myasthenia gravis from 1998 to 2022: A bibliometric analysis

BACKGROUND: The treatment of myasthenia gravis (MG) has advanced from steroids and traditional immunosuppressants to targeted immunotherapy. Targeted immunotherapy has been successfully employed in clinical practice in recent years. This study aimed to explore the emerging trend of targeted immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Yue, Ruan, Zhe, Wang, Rui, Hao, Sijia, Tang, Yonglan, Huang, Xiaoxi, Gao, Ting, Li, Zhuyi, Chang, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557176/ https://www.ncbi.nlm.nih.gov/pubmed/36248874 http://dx.doi.org/10.3389/fimmu.2022.998217

Ejemplares similares

Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis
por: Jiang, Fan, et al.
Publicado: (2023)

Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis
por: Ruan, Zhe, et al.
Publicado: (2022)

COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series
por: Ruan, Zhe, et al.
Publicado: (2021)

Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis
por: Li, Shuang, et al.
Publicado: (2023)

Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis
por: Su, Yue, et al.
Publicado: (2023)

Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023)

Lack of Immunotherapy as the Only Predictor of Secondary Generalization in Very-Late-Onset Myasthenia Gravis With Pure Ocular Onset
por: Zhao, Sijia, et al.
Publicado: (2022)

Novel Immunotherapies for Myasthenia Gravis
por: Nair, Sruthi S, et al.
Publicado: (2023)

Regulatory B Cells Are Decreased and Functionally Impaired in Myasthenia Gravis Patients
por: Lin, Ye, et al.
Publicado: (2022)

Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
por: Shen, Jianming, et al.
Publicado: (2022)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Muscle-Specific Kinase Myasthenia Gravis
por: Borges, Lucia S., et al.
Publicado: (2020)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis
por: Zhou, Qian, et al.
Publicado: (2021)

Melatonin exerts immunoregulatory effects by balancing peripheral effector and regulatory T helper cells in myasthenia gravis
por: Chang, Ting, et al.
Publicado: (2020)

Decreased expression of circulating Aire and increased Tfh/Tfr cells in myasthenia gravis patients
por: Zhao, Sijia, et al.
Publicado: (2018)

Knowledge mapping of autophagy in osteoarthritis from 2004 to 2022: A bibliometric analysis
por: Liao, Jiahe, et al.
Publicado: (2023)

Extraocular Muscle Characteristics Related to Myasthenia Gravis Susceptibility
por: Liu, Rui, et al.
Publicado: (2013)

Safety of COVID-19 vaccine in patients with myasthenia gravis: a self-controlled case series study
por: Ruan, Zhe, et al.
Publicado: (2023)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China
por: Ding, Jiaqi, et al.
Publicado: (2020)

Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis
por: Wang, Shumin, et al.
Publicado: (2021)

Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study
por: Zhong, Weibo, et al.
Publicado: (2022)

Role of miRNAs in Normal and Myasthenia Gravis Thymus
por: Cron, Mélanie A., et al.
Publicado: (2020)

Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis
por: Xiao, Hai, et al.
Publicado: (2021)

Knowledge mapping and research trends of IL-33 from 2004 to 2022: a bibliometric analysis
por: Jin, Jingyi, et al.
Publicado: (2023)

Immunotherapy choice and maintenance for generalized myasthenia gravis in China
por: Zhang, Chao, et al.
Publicado: (2020)

Benefit and danger from immunotherapy in myasthenia gravis
por: Rodolico, Carmelo, et al.
Publicado: (2021)

Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis
por: Li, Mingxia, et al.
Publicado: (2019)

Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis
por: Gable, Karissa L., et al.
Publicado: (2020)

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
por: Huda, Ruksana
Publicado: (2020)

Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases
por: Zhu, Ying, et al.
Publicado: (2023)

Immunotherapy for ocular myasthenia gravis: an observational study in Japan
por: Narita, Tomoko, et al.
Publicado: (2023)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Cannot write session to /tmp/vufind_sessions/sess_53dec217lsi79frshec1dea012